CHF-5074
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 513689

CAS#: 749269-83-8

Description: CHF-5074, also known as CSP-1103, is a γ-secretase modulator. CHF-5074 reduces Aβ42 and Aβ40 secretion, with an IC50 of 3.6 and 18.4 μM respectively. CHF5074 reduces brain beta-Amyloid pathology in a transgenic mouse model of Alzheimer's Disease without causing peripheral toxicity. CHF5074 is a non-steroidal anti-inflammatory derivative holding disease-modifying potential for the treatment of Alzheimer's disease.


Chemical Structure

img
CHF-5074
CAS# 749269-83-8

Theoretical Analysis

MedKoo Cat#: 513689
Name: CHF-5074
CAS#: 749269-83-8
Chemical Formula: C16H11Cl2FO2
Exact Mass: 324.01
Molecular Weight: 325.160
Elemental Analysis: C, 59.10; H, 3.41; Cl, 21.80; F, 5.84; O, 9.84

Price and Availability

Size Price Availability Quantity
5mg USD 90 Ready to ship
10mg USD 150 Ready to ship
25mg USD 250 Ready to ship
50mg USD 450 Ready to ship
100mg USD 750 Ready to ship
200mg USD 1250 Ready to ship
500mg USD 2650 Ready to ship
Bulk inquiry

Synonym: CHF-5074; CHF5074; CHF 5074; CSP-1103; CSP 1103; CSP1103; Itanapraced

IUPAC/Chemical Name: 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid

InChi Key: LIYLTQQDABRNRX-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H11Cl2FO2/c17-12-4-1-9(7-13(12)18)11-3-2-10(8-14(11)19)16(5-6-16)15(20)21/h1-4,7-8H,5-6H2,(H,20,21)

SMILES Code: O=C(C1(C2=CC=C(C3=CC=C(Cl)C(Cl)=C3)C(F)=C2)CC1)O

Appearance: Solid powder

Purity: >97% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Itanapraced (CHF5074) is a novel γ-secretase modulator, reduces Aβ42 and Aβ40 secretion, with an IC50 of 3.6 and 18.4 μM, respectively.
In vitro activity: Here, the effects of CHF5074 on Aβ25-35- triggered TRAIL toxicity were evaluated in the differentiated human neuroblastoma cell line SH-SY5Y in vitro. Cells were pre-treated 1h with CHF5074 at graded concentrations (range: 1 nM-1 uM) and then challenged for 72 h with either Aβ25-35 or TRAIL. Results show that CHF5074 treatment prevented apoptotic death in SH-SY5Y cell line in a concentration- dependent fashion. Its maximally active concentration was 10 nM. Then, investigation of related molecular mechanisms underlying such protective effect of CHF5074 suggested that the levels of caspases, as well as of various kinases, including stress and MAP kinases, are modulated by CHF5074. Finally, treatment of injured human neuroblastoma cell line SH-SY5Y with CHF5074 resulted in prominent protection from apoptotic death. The bulk of these data suggest that CHF5074 represents a potential candidate for pharmacological neuroprotective treatment in neurodegenerative disorders. Reference: Curr Alzheimer Res. 2014;11(7):714-24. https://www.eurekaselect.com/122812/article
In vivo activity: Compared with transgenic controls, CHF5074 treatment significantly reduced the area occupied by plaques in cortex (P = 0.003) and hippocampus (P = 0.004). The number of plaques were also reduced by CHF5074 in both cortex (P = 0.022) and hippocampus (P = 0.005). Plaque-associated microglia in CHF5074-treated animals was lower than in transgenic controls in cortex (P = 0.008) and hippocampus (P = 0.002). Ibuprofen treatment significantly reduced microglia area in cortex and hippocampus but not beta-amyloid burden. On the last day of the Morris water maze, transgenic controls performed significantly worse than the non-transgenic animals and the CHF5074-treated transgenic mice, on the swimming path to reach the hidden platform. Ibuprofen-treated animals did not perform significantly better than transgenic controls. Reference: Br J Pharmacol. 2009 Mar;156(6):982-93. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19239474/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 59.0 181.45

Preparing Stock Solutions

The following data is based on the product molecular weight 325.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol: 1. Ronsisvalle N, Di Benedetto G, Parenti C, Amoroso S, Bernardini R, Cantarella G. CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro. Curr Alzheimer Res. 2014;11(7):714-24. doi: 10.2174/1567205011666140618104430. PMID: 24938499. 2. Mango D, Barbato G, Piccirilli S, Panico MB, Feligioni M, Schepisi C, Graziani M, Porrini V, Benarese M, Lanzillotta A, Pizzi M, Pieraccini S, Sironi M, Blandini F, Nicoletti F, Mercuri NB, Imbimbo BP, Nisticò R. Electrophysiological and metabolic effects of CHF5074 in the hippocampus: protection against in vitro ischemia. Pharmacol Res. 2014 Mar;81:83-90. doi: 10.1016/j.phrs.2014.02.010. Epub 2014 Mar 12. PMID: 24630950.
In vivo protocol: 1. Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol. 2009 Mar;156(6):982-93. doi: 10.1111/j.1476-5381.2008.00097.x. PMID: 19239474; PMCID: PMC2697723. 2. Giuliani A, Beggiato S, Baldassarro VA, Mangano C, Giardino L, Imbimbo BP, Antonelli T, Calzà L, Ferraro L. CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice. J Neurochem. 2013 Mar;124(5):613-20. doi: 10.1111/jnc.12136. Epub 2013 Jan 28. PMID: 23278303.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Mu Y, Jin S, Shen J, Sugano A, Takaoka Y, Qiang L, Imbimbo BP, Yamamura K, Li Z. CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci. FEBS Lett. 2015 Mar 24;589(7):849-56. doi: 10.1016/j.febslet.2015.02.020. PubMed PMID: 25728271.

2: Porrini V, Lanzillotta A, Branca C, Benarese M, Parrella E, Lorenzini L, Calzà L, Flaibani R, Spano PF, Imbimbo BP, Pizzi M. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. Neuroscience. 2015 Aug 27;302:112-20. doi: 10.1016/j.neuroscience.2014.10.029. PubMed PMID: 25450955.

3: Ronsisvalle N, Di Benedetto G, Parenti C, Amoroso S, Bernardini R, Cantarella G. CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro. Curr Alzheimer Res. 2014;11(7):714-24. PubMed PMID: 24938499.

4: Branca C, Sarnico I, Ruotolo R, Lanzillotta A, Viscomi AR, Benarese M, Porrini V, Lorenzini L, Calzà L, Imbimbo BP, Ottonello S, Pizzi M. Pharmacological targeting of the β-amyloid precursor protein intracellular domain. Sci Rep. 2014 Apr 9;4:4618. doi: 10.1038/srep04618. PubMed PMID: 24714650; PubMed Central PMCID: PMC3980230.